On May 13, 2024, Ajax Therapeutics, Inc. closed the transaction. The transaction was led by new investor, The Goldman Sachs Group, Inc. and also included participation from new investors, Eli Lilly and Company, Vivo Capital, LLC, RA Capital Management, L.P., Point72 Asset Management, L.P. and returning investors, Boxer Capital LLC, Inning One Ventures, L.P., EcoR1 Capital, LLC and Schrödinger, Inc. The round was oversubscribed. As part of the transaction, Amit Sinha and Ming Cheah of The Goldman Sachs Group, Inc. will join company's board.

The transaction included participation from 21 investors pursuant to exemption provided under Regulation D.